Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market is estimated to be worth around USD 2

Тема в разделе "Заявки на разбан", создана пользователем Stella Wilson, 22 апр 2021.

  1. Stella Wilson

    Stella Wilson New Member

    Nearly 300 non-invasive diagnostic tests, designed for the detection of various types of cancers, are either already available in the market or under development across the world

    Given the invasive and cost-intensive nature of tissue biopsies, there is a significant unmet need for safer and more patient-friendly cancer diagnostics that are capable of offering highly accurate, and actionable insights related to the disease.

    Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market, Forecast to 2030

    The financial opportunity within the liquid biopsy and other non-invasive cancer diagnostics market has been analyzed across the following segments:

    Type of Tumor Marker

    · ctDNA

    · cfDNA

    · of CTCs

    · exosomes

    · Others Others


    · Diagnosis / The Early Diagnosis

    · Patient the Monitoring

    · Recurrence the Monitoring

    Target Cancer Indication

    · Breast Cancer

    · Lung Cancer

    · Colorectal Cancer

    · Prostate Cancer

    · Bladder Cancer

    · Melanoma

    · Gastric Cancer

    · Pancreatic Cancer

    · Ovarian Cancer

    · Others Others

    End Users

    · Hospitals

    · Research Institutes

    · Others Others

    Key Geographical Regions

    · North America

    · Europe

    · Asia-Pacific

    · Rest of the World

    Get Latest Market Insights:

    Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market is estimated to be worth around USD 20.1 billion by 2030

    The Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers report features the following companies, which we identified to be key players in this domain:

    Key Players:

    · The Amoy Diagnostics

    · DiaCarta

    · HaploX Biotechnology

    · NeoGenomics

    · a QIAGEN

    · Swift Biosciences

    · Sysmex Inostics

    · The Thermo Fisher Scientific

    Table of Contents

    1. Preface

    2. Executive Summary

    3. Introduction

    4. Non-Invasive Cancer Screening and Diagnosis

    5. Market Landscape

    6. Company Profiles

    7. Partnerships and Collaborations

    8. Funding and Investment Analysis

    9. Liquid Biopsy: Initiatives of Big Pharma Players

    10. Key Acquisition Targets

    11. Other Non-Invasive Cancer Diagnostics

    12. Market Sizing and Opportunity Analysis

    13. Survey Insights

    14. Conclusion

    15. Executive Insights

    16. Appendix 1: Tabulated Data

    17. Appendix 2: List of Companies and Organizations

    Request for Customization:
    оформить кредит онлайн не выходя из дома, вы всегда сможете купить платные шаблоны для dle по выгодной цене

Поделиться этой страницей